Commercialization of Cardiac Resident Stem Cell Regenerative Medicine through a Capital and Business Alliance with JRM
First written in FY2017-Q2. 13 of 21 entries say "Restated". Latest entry: FY2023-Q3.
No other company in this theme has enough history to compare yet.
- FY2023-Q3Cited as achievedAnnual report
「Regarding the cardiac resident stem cell (CSC) pipeline JRM-001, which we had been pursuing with SHED, we determined that the best course of action was to transfer the business to メトセラ, which has research and development experience and expertise in the field of heart disease and would lead development, while continuing partnering activities aimed at future commercialization. Accordingly, we resolved on 4 April 2022 to transfer all shares of Japan Regenerative Medicine Co., Ltd., our wholly owned subsidiary developing JRM-001, and completed the transfer. We will continue to support development activities.」
For JRM-001, the transfer of all shares of Japan Regenerative Medicine and the transition to development led by メトセラ are being reiterated as completed initiatives, with the company stating that it will continue to support development. - FY2023-Q2Cited as achievedAnnual report
「Regarding the cardiac resident stem cell (CSC) pipeline JRM-001, which we had been pursuing with SHED, we determined that the best course of action was to transfer the business to メトセラ, which has research and development experience and expertise in the field of heart disease and would lead development, while continuing partnering activities aimed at future commercialization. Accordingly, we resolved on 4 April 2022 to transfer all shares of Japan Regenerative Medicine Co., Ltd., our wholly owned subsidiary developing JRM-001, and completed the transfer. We will continue to support development activities.」
For JRM-001, the transfer of all shares of Japan Regenerative Medicine and the transition to development led by メトセラ are being reiterated as completed initiatives, with the company stating that it will continue to support development. - FY2023-Q1Cited as achievedAnnual report
「Regarding the cardiac resident stem cell (CSC) pipeline JRM-001, which we had been pursuing with SHED, we determined that the best course of action was to transfer the business to メトセラ, which has research and development experience and expertise in the field of heart disease and would lead development, while continuing partnering activities aimed at future commercialization. Accordingly, we resolved on 4 April 2022 to transfer all shares of Japan Regenerative Medicine Co., Ltd., our wholly owned subsidiary developing JRM-001, and completed the transfer. We will continue to support development activities.」
The transfer of all shares of Japan Regenerative Medicine, including JRM-001, and the transition to development led by メトセラ are being reiterated as completed initiatives, with the company stating that it will continue to support development. - FY2022ReframedAnnual report
「We determined that the best course of action was to transfer this business to メトセラ, which has research and development experience and expertise in the field of heart disease and would lead development. Accordingly, we resolved on 4 April 2022 to transfer the shares of Japan Regenerative Medicine Co., Ltd., our wholly owned subsidiary developing JRM-001, and completed the transfer. Going forward, we will remain involved in development by supporting development activities.」
For JRM-001, which had been advanced through the acquisition of Japan Regenerative Medicine as a wholly owned subsidiary, the business and shares were transferred to メトセラ, and the project moved to a structure in which we support development led by that company. - FY2022-Q3RestatedAnnual report
「For CSC, we are advancing development of the regenerative medical product JRM-001, primarily targeting functional single-ventricle syndrome, a serious pediatric heart disease. In October 2020, Japan Tissue Engineering Co., Ltd., which has extensive experience commercializing autologous regenerative medical products using autologous cells derived from patients' own tissue, was added as the manufacturing partner for the Phase 3 clinical trial of the development product. In June 2021, the product was designated by the Ministry of Health, Labour and Welfare as a regenerative medical product for a rare disease.」
We continue to develop JRM-001 by utilizing the manufacturing structure with Japan Tissue Engineering and its designation as a regenerative medical product for a rare disease. - FY2022-Q2RestatedAnnual report
「For CSC, we are advancing development of the regenerative medical product JRM-001, primarily targeting functional single-ventricle syndrome, a serious pediatric heart disease. In October 2020, Japan Tissue Engineering Co., Ltd., which has extensive experience commercializing autologous regenerative medical products using autologous cells derived from patients' own tissue, was added as the manufacturing partner for the Phase 3 clinical trial of the development product. In June 2021, the product was designated by the Ministry of Health, Labour and Welfare as a regenerative medical product for a rare disease.」
We continue to develop JRM-001 by utilizing the manufacturing structure with Japan Tissue Engineering and its designation as a regenerative medical product for a rare disease. - FY2022-Q1AdvancedAnnual report
「In October 2020, Japan Tissue Engineering Co., Ltd., which has extensive experience commercializing autologous regenerative medical products using autologous cells derived from patients' own tissue, was added as the manufacturing partner for the Phase 3 clinical trial of the development product. In June 2021, the product was designated by the Ministry of Health, Labour and Welfare as a regenerative medical product for a rare disease. Going forward, we will accelerate the clinical trial further by making maximum use of efficient collaboration with the manufacturing partner and the preferential measures available following the designation, including priority consultation and review for clinical trials and an extended re-examination period.」
Following the addition of a manufacturing partner, JRM-001 was designated a regenerative medical product for a rare disease in June 2021. The company has indicated a policy of accelerating the clinical trial by using measures such as priority consultation and review for clinical trials. - FY2021-Q3AdvancedAnnual report
「In October 2020, for the Phase 3 clinical trial of this development candidate, we added ジャパン・ティッシュ・エンジニアリング㈱ as a manufacturing partner. The company has extensive experience commercializing autologous regenerative medical products using autologous cells derived from patients' own tissues. By establishing a stable manufacturing structure for this development candidate using the company's manufacturing technology, we expect to further accelerate this clinical trial using autologous cells.」
For JRM-001, Japan Tissue Engineering was added as the manufacturing partner for the Phase 3 clinical trial, advancing the project to the stage of establishing a stable manufacturing structure and accelerating the clinical trial. - FY2021-Q1RestatedAnnual report
「Regarding cardiac resident stem cells, we made Japan Regenerative Medicine Co., Ltd., with which we had previously maintained a capital alliance, a wholly owned subsidiary in the previous consolidated fiscal year. This added to our pipeline the development product JRM-001, a regenerative medical product primarily targeting functional single-ventricle syndrome, a serious pediatric heart disease. We are accelerating development by investing our commercialization expertise, technology and development funding.」
The inclusion of JRM-001 in our proprietary pipeline following the acquisition of Japan Regenerative Medicine as a wholly owned subsidiary, and the policy of advancing development by investing commercialization expertise, technology and development funding, are being reaffirmed. - FY2020AdvancedAnnual report
「Japan Regenerative Medicine Co., Ltd. became a wholly owned subsidiary through the acquisition of shares from Noritsu Koki Co., Ltd. in February 2020.」
The cardiac resident stem cell regenerative medicine project under the capital and business alliance with JRM progressed through the acquisition of all shares in the company and the inclusion of JRM-001 in our proprietary pipeline. - FY2020-Q3RestatedAnnual report
「Going forward, in addition to the cardiac resident stem cell project of Japan Regenerative Medicine, on which we have been working, we will establish a cell therapy platform for our regenerative medicine business based on Cell Technology's dental pulp stem cells, enabling us to pursue various business initiatives, including the development of new products and treatments.」
The policy of continuing the Japan Regenerative Medicine cardiac resident stem cell project and seeking to establish a cell therapy platform combined with Cell Technology's dental pulp stem cells is being reaffirmed. - FY2020-Q1RestatedAnnual report
「In October 2016, we formed a capital and business alliance with Japan Regenerative Medicine Co., Ltd., a member of the Noritsu Koki Co.,Ltd. group, and are working to expand the regenerative medicine business with the aim of commercializing regenerative medical products using cardiac resident stem cells currently under development by that company.」
The commercialization of regenerative medical products using cardiac resident stem cells under the capital and business alliance with Japan Regenerative Medicine and the expansion of the regenerative medicine field are being reaffirmed. - FY2019RestatedAnnual report
「In October 2016, we formed a capital and business alliance with Japan Regenerative Medicine Co., Ltd., a member of the Noritsu Koki Co.,Ltd. group, and are working to expand the regenerative medicine business with the aim of commercializing regenerative medical products using cardiac resident stem cells currently under development by that company.」
We continue to commercialize cardiac resident stem cell regenerative medicine under the capital and business alliance with JRM. - FY2019-Q2RestatedAnnual report
「In the field of regenerative medicine, which constitutes our new biotechnology business, we formed a capital and business alliance in October 2016 with Japan Regenerative Medicine Co., Ltd., also a member of the Noritsu Koki Co.,Ltd. group, and are working across the group to expand the regenerative medicine business with the aim of commercializing regenerative medical products using cardiac resident stem cells currently under development by that company.」
We continue to commercialize cardiac resident stem cell regenerative medicine under the capital and business alliance with JRM and expand the group's regenerative medicine operations. - FY2019-Q1RestatedAnnual report
「In the field of regenerative medicine, which constitutes our new biotechnology business, we formed a capital and business alliance in October 2016 with Japan Regenerative Medicine Co., Ltd., also a member of the Noritsu Koki Co.,Ltd. group, and are working across the group to expand the regenerative medicine business with the aim of commercializing regenerative medical products using cardiac resident stem cells currently under development by that company.」
We continue to commercialize cardiac resident stem cell regenerative medicine under the capital and business alliance with JRM and expand the regenerative medicine business through the group. - FY2018RestatedAnnual report
「In the field of regenerative medicine, which constitutes our new biotechnology business, we formed a capital and business alliance in October 2016 with Japan Regenerative Medicine Co., Ltd., also a member of the Noritsu Koki Co.,Ltd. group, and are working across the group to expand the regenerative medicine business with the aim of commercializing regenerative medical products using cardiac resident stem cells currently under development by that company.」
We continue the joint commercialization of cardiac resident cell regenerative medicine under the capital and business alliance with JRM and the expansion of the regenerative medicine business through the group. - FY2018-Q3RestatedAnnual report
「In the field of regenerative medicine, which constitutes our new biotechnology business, we formed a capital and business alliance in October 2016 with Japan Regenerative Medicine Co., Ltd., also a member of the Noritsu Koki Co.,Ltd. group, and are working across the group to expand the regenerative medicine business with the aim of commercializing regenerative medical products using cardiac resident stem cells currently under development by that company.」
We continue to commercialize cardiac resident stem cell regenerative medicine under the capital and business alliance with JRM and expand the regenerative medicine business within the group. - FY2018-Q2RestatedAnnual report
「In the field of regenerative medicine, which constitutes our new biotechnology business, we formed a capital and business alliance in October 2016 with Japan Regenerative Medicine Co., Ltd., also a member of the Noritsu Koki Co.,Ltd. group, and are working across the group to expand the regenerative medicine business with the aim of commercializing regenerative medical products using cardiac resident stem cells currently under development by that company.」
We continue to commercialize cardiac resident stem cell regenerative medicine under the capital and business alliance with JRM and expand the regenerative medicine business through the group. - FY2017RestatedAnnual report
「In the field of regenerative medicine, we formed a capital and business alliance in October 2016 with Japan Regenerative Medicine Co., Ltd., also a member of the Noritsu Koki Co.,Ltd. group, and are working across the group to expand the regenerative medicine business with the aim of commercializing regenerative medical products using cardiac resident stem cells currently under development by that company.」
We continue to commercialize cardiac resident stem cell regenerative medicine under the capital and business alliance with JRM and expand the regenerative medicine business through the group. - FY2017-Q3RestatedAnnual report
「In the field of regenerative medicine, we formed a capital and business alliance in October 2016 with Japan Regenerative Medicine Co., Ltd., also a member of the Noritsu Koki Co.,Ltd. group, and are working across the group to expand the regenerative medicine business with the aim of commercializing regenerative medical products using cardiac resident stem cells currently under development by that company.」
We continue to commercialize cardiac resident stem cell regenerative medicine under the capital and business alliance with JRM and expand the regenerative medicine business across the group. - FY2017-Q2First statedAnnual report
「Based on a resolution of our Board of Directors meeting held on 13 October 2016, we entered into a capital and business alliance agreement with Japan Regenerative Medicine Co., Ltd. (hereinafter, “JRM”) on 21 October 2016 (hereinafter, the “Alliance”).」
We entered into a capital and business alliance with JRM, a member of the Noritsu Koki Co.,Ltd. group, and will support the commercialization of regenerative medical products using cardiac resident stem cells by leveraging expertise in biopharmaceutical research and development, manufacturing, regulatory affairs, business development and human resources networks.